{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:28:50Z","timestamp":1792546130021,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.apsb.2024.10.012","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T20:59:52Z","timestamp":1730926792000},"page":"669-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin \u03b1v\u03b23-positive tumors: A first-in-human study"],"prefix":"10.1016","volume":"15","author":[{"given":"Huimin","family":"Sui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-2441","authenticated-orcid":false,"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0042-7468","authenticated-orcid":false,"given":"Yingkui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.10.012_bib1","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMcibr2209679","article-title":"Integrins in health and disease","volume":"387","author":"Fagerholm","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00441-009-0834-6","article-title":"Integrins","volume":"339","author":"Barczyk","year":"2010","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.apsb.2024.10.012_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108458","article-title":"Integrins in cancer: emerging mechanisms and therapeutic opportunities","volume":"247","author":"Liu","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2024.10.012_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.10.012_bib5","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/cancers13071711","article-title":"RGD-binding integrins revisited: how recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field","volume":"13","author":"Ludwig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2024.10.012_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2174\/1874471016666221207122731","article-title":"An overview of radiolabeled RGD peptides for theranostic applications","volume":"16","author":"Badipa","year":"2023","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.apsb.2024.10.012_bib7","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/cbic.202000626","article-title":"Biological relevance of RGD-integrin subtype-specific ligands in cancer","volume":"22","author":"Sani","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.apsb.2024.10.012_bib8","article-title":"Preliminary clinical application of RGD-containing peptides as PET radiotracers for imaging tumors","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2024.10.012_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7150\/thno.13242","article-title":"Clinical application of radiolabeled RGD peptides for PET imaging of integrin \u03b1v\u03b23","volume":"6","author":"Chen","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2024.10.012_bib10","article-title":"Advances in clinical oncology research on 99mTc-3PRGD2 SPECT Imaging","volume":"12","author":"Xiao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2024.10.012_bib11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1148\/radiol.2016150813","article-title":"Integrin imaging with 99mTc-3PRGD2 SPECT\/CT shows high specificity in the diagnosis of lymph node metastasis from non-small cell lung cancer","volume":"281","author":"Jin","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.apsb.2024.10.012_bib12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.111.098988","article-title":"99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study","volume":"53","author":"Zhu","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2967\/jnumed.115.160648","article-title":"68Ga-NOTA-PRGD2 PET\/CT for integrin imaging in patients with lung cancer","volume":"56","author":"Zheng","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib14","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/RLU.0000000000002233","article-title":"Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET\/CT can discriminate uncommon meningioma mimicking high-grade glioma","volume":"43","author":"Li","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.semnuclmed.2019.07.006","article-title":"Targeted radionuclide therapy: a historical and personal review","volume":"50","author":"Goldsmith","year":"2020","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib16","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","article-title":"Targeted radionuclide therapy in combined-modality regimens","volume":"18","author":"Gill","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2024.10.012_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00259-014-2891-7","article-title":"Targeted radionuclide therapy with RAFT-RGD radiolabelled with 90Y or 177Lu in a mouse model of \u03b1v\u03b23-expressing tumors","volume":"42","author":"Bozon-Petitprin","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.apsb.2024.10.012_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7150\/thno.7781","article-title":"Anti-tumor effect of integrin targeted 177Lu-3PRGD2 and combined therapy with Endostar","volume":"4","author":"Shi","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2024.10.012_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104100","article-title":"177Lu-labeled cyclic RGD peptide as an imaging and targeted radionuclide therapeutic agent in non-small cell lung cancer: biological evaluation and preclinical study","volume":"102","author":"Pirooznia","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2024.10.012_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/acs.bioconjchem.8b00919","article-title":"Bench to bedside: albumin binders for improved cancer radioligand therapies","volume":"30","author":"Lau","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2024.10.012_bib23","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-19-1098","article-title":"Targeted radionuclide therapy in patient-derived xenografts using 177Lu-EB-RGD","volume":"19","author":"Zhao","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2024.10.012_bib24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/pharmaceutics14071327","article-title":"Palmitic acid-conjugated radiopharmaceutical for integrin \u03b1v\u03b23-targeted radionuclide therapy","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2024.10.012_bib25","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2024.10.012_bib27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2967\/jnumed.111.088955","article-title":"Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET\/CT in monkeys and humans","volume":"53","author":"Doss","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MNM.0000000000001814","article-title":"Safety, biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 99mTc-maraciclatide in healthy volunteers","volume":"45","author":"Gibbons","year":"2024","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.apsb.2024.10.012_bib29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/diagnostics12040851","article-title":"First-in-human study of [68Ga]Ga-NODAGA-E[c(RGDyK)](2) PET for integrin \u03b1v\u03b23 imaging in patients with breast cancer and neuroendocrine neoplasms: safety, dosimetry, and tumor imaging ability","volume":"12","author":"Clausen","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.apsb.2024.10.012_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.apsb.2024.10.012_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101295","article-title":"Nephrotoxicity after radionuclide therapies","volume":"15","author":"Parihar","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.apsb.2024.10.012_bib32","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2967\/jnumed.121.263056","article-title":"Safety of peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients with chronic kidney disease","volume":"63","author":"Alsadik","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","article-title":"First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Zang","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.apsb.2024.10.012_bib34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2967\/jnumed.118.209841","article-title":"Safety, Pharmacokinetics, and dosimetry of a long-acting radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in patients with advanced metastatic neuroendocrine tumors","volume":"59","author":"Zhang","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2024.10.012_bib35","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1007\/s00259-024-06721-x","article-title":"Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study","volume":"51","author":"Li","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524004131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524004131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:39:28Z","timestamp":1741678768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524004131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2211383524004131"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.10.012","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin \u03b1v\u03b23-positive tumors: A first-in-human study","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}